SciELO - Scientific Electronic Library Online

 
vol.26 número3Mesotelioma maligno: Experiencia clínico-patológica de 247 casosDisnea súbita después del terremoto índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Revista chilena de enfermedades respiratorias

versión On-line ISSN 0717-7348

Resumen

SANTINI B, ALEJANDRO et al. High dose rate endobronchial brachytherapy in patients with central airway obstruction. Rev. chil. enferm. respir. [online]. 2010, vol.26, n.3, pp.141-148. ISSN 0717-7348.  http://dx.doi.org/10.4067/S0717-73482010000300004.

Introduction: The main indication of modern high dose rate end bronchial brachyherapy (HDR EBBT) is the palliation of symptoms related to the growth of the endobronchial lung cancer. Methods: EBBT was performed to 27 patients who suffered symptomatic tumoral endobronchial or tracheal pathology, due to primary bronchial disease or secondary metastasis cancer, evaluating the rate of clinical benefit. The tumors were located at tracheal, carinal or proximal bronchial level. Fibrobronchoscopy was performed to all the patients to measure the degree of airway obstruction and to install brachytherapy endobronchial catheters. Between 1 to 4 fractions of 7 to 7.5 Gy were administered. Dyspnea, cough and hemoptysis were subjectively registered before and after treatment, according to an international validated scale. Results: After treatment, all symptoms considerably decreased, disappearing all of the severe categories. Hemoptysis and dyspnea resolved in a 100% and 40% of patients, respectively; and cough disappeared or was reduced to a minimum grade in 90% of cases.

Palabras clave : Endobronchial brachytherapy HDR; endobronchial lung cancer; tracheal pathology.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons